SCHEMBL21261020

SCHEMBL21261020

Cn1cc(C(=O)Nc2sc3c(c2C(=O)O)CC(C)(C)CC3)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB7A P51149 1/20 0.57
▸ FABP4 P15090 2/20 0.48
▸ FABP5 Q01469 2/20 0.48
▸ KIF11 P52732 1/20 0.47
▸ MEN1 O00255 10/20 0.47
▸ KMT2A Q03164 10/20 0.47
▸ MAPT P10636 7/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ LMNA P02545 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ ESR2 Q92731 1/20 0.45
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ GRIN2C Q14957 2/20 0.43
▸ MITF O75030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21261056 0.93 RAB7A (0.48) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL21261032 0.84 RAB7A (0.60) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL21247382 0.82 RAB7A (0.80) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL21261018 0.81 PTPN1 (0.60) RAB7AMEN1KMT2AMAPTRAB9A
SCHEMBL21247202 0.80 TNF (0.68) RAB7AKIF11MEN1KMT2AMAPT
SCHEMBL21247157 0.78 RAB7A (0.52) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL19321164 0.77 RAB7A (0.52) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL19321160 0.76 RAB7A (0.62) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL19326363 0.76 RAB7A (0.52) RAB7AFABP4FABP5KIF11MEN1
SCHEMBL19325776 0.76 RAB7A (0.61) RAB7AFABP4FABP5KIF11MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11492347-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2022-11-08 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-19 — — US disclosed
CN-111954668-A Fused thiophene derivative and use thereof 埃尼奥制药公司 2020-11-17 — — CN disclosed
WO-2019154950-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361924-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH RAB7A 2283/4885FABP4 331/4885FABP5 350/4885
US-11492347-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH RAB7A 2283/4885FABP4 331/4885FABP5 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback